Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer

被引:9
作者
Shu, Sei [1 ,3 ]
Iimori, Makoto [2 ]
Nakanishi, Ryota [1 ]
Jogo, Tomoko [1 ]
Saeki, Hiroshi [1 ]
Oki, Eiji [1 ]
Maehara, Yoshihiko [1 ,4 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Fukuoka, Japan
[2] Kyushu Univ, Dept Mol Canc Biol, Fukuoka, Fukuoka, Japan
[3] Chugai Pharmaceut Co Ltd, Med Affairs Div, Prod Res Dept, Kamakura, Kanagawa, Japan
[4] Mutual Aid Assoc Publ Sch Teachers, Kyushu Cent Hosp, Fukuoka, Fukuoka, Japan
来源
IN VIVO | 2018年 / 32卷 / 06期
关键词
HER2; gastric cancer; trastuzumab; IN-SITU HYBRIDIZATION; FACTOR RECEPTOR 2; CLINICOPATHOLOGICAL CHARACTERISTICS; TRASTUZUMAB EMTANSINE; CELL-PROLIFERATION; ANTITUMOR-ACTIVITY; SCORING SYSTEM; C-MET; THERAPY; PROGNOSIS;
D O I
10.21873/invivo.11405
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: It is essential to establish a strategy for second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer; however, HER2 expression status after chemotherapy treatment is not routinely determined. Materials and Methods: We analyzed 25 cases of gastric cancer that received preoperative chemotherapy and selected the six pre-treatment samples that were HER2-positive. Pre- and post-treatment tumor samples were examined for HER2 expression, and for HER2, epidermal growth factor receptor (EGFR), and hepatocyte growth factor receptor (MET) gene amplification. Results: Three patients had been treated with trastuzumab plus chemotherapy, and three patients with cytotoxic chemotherapy alone. Only one case that had an initial HER2 score of 3+ and had received trastuzumab plus chemotherapy remained HER2-positive after treatment. Decrease or loss of HER2 expression and amplification was observed in the other five patients. Amplification of EGFR or MET was not observed in any pre-or post-treatment specimens. Conclusion: Our data suggest that trastuzumab plus chemotherapy or chemotherapy alone may induce loss of HER2 positivity.
引用
收藏
页码:1491 / 1498
页数:8
相关论文
共 35 条
[1]   HER2 testing in gastric cancer: An update [J].
Abrahao-Machado, Lucas Faria ;
Scapulatempo-Neto, Cristovam .
WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (19) :4619-4625
[2]  
Bang YJ, 2010, LANCET, V376, P1302
[3]  
Baselga J, 1997, Oncology (Williston Park), V11, P43
[4]  
Baselga J, 1998, CANCER RES, V58, P2825
[5]   HER2 induces cell proliferation and invasion of non-small-cell lung cancer by upregulating COX-2 expression via MEK/ERK signaling pathway [J].
Chi, Feng ;
Wu, Rong ;
Jin, Xueying ;
Jiang, Min ;
Zhu, Xike .
ONCOTARGETS AND THERAPY, 2016, 9 :2709-2716
[6]   A mathematical model for the effects of HER2 overexpression on cell proliferation in breast cancer [J].
Eladdadi, Amina ;
Isaacson, David .
BULLETIN OF MATHEMATICAL BIOLOGY, 2008, 70 (06) :1707-1729
[7]   Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models [J].
Fujimoto-Ouchi, Kaori ;
Sekiguchi, Fumiko ;
Yasuno, Hideyuki ;
Moriya, Yoichiro ;
Mori, Kazushige ;
Tanaka, Yutaka .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (06) :795-805
[8]   Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients [J].
Fuse, Nozomu ;
Kuboki, Yasutoshi ;
Kuwata, Takeshi ;
Nishina, Tomohiro ;
Kadowaki, Shigenori ;
Shinozaki, Eiji ;
Machida, Nozomu ;
Yuki, Satoshi ;
Ooki, Akira ;
Kajiura, Shinya ;
Kimura, Tetsuo ;
Yamanaka, Takeharu ;
Shitara, Kohei ;
Nagatsuma, Akiko Kawano ;
Yoshino, Takayuki ;
Ochiai, Atsushi ;
Ohtsu, Atsushi .
GASTRIC CANCER, 2016, 19 (01) :183-191
[9]   HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target [J].
Gravalos, C. ;
Jimeno, A. .
ANNALS OF ONCOLOGY, 2008, 19 (09) :1523-1529
[10]   Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients [J].
Guarneri, V. ;
Dieci, M. V. ;
Barbieri, E. ;
Piacentini, F. ;
Omarini, C. ;
Ficarra, G. ;
Bettelli, S. ;
Conte, P. F. .
ANNALS OF ONCOLOGY, 2013, 24 (12) :2990-2994